Author: Alisha GC
Bispecific antibodies represent an innovative class of engineered immunotherapeutics that can simultaneously bind two different antigens. By bridging immune effector cells with tumor cells, these molecules enable targeted immune-mediated cytotoxicity and overcome several limitations associated with traditional monoclonal antibody therapies. Many bispecific antibodies are designed to recruit cytotoxic T lymphocytes through CD3 engagement while targeting tumor-associated antigens such as CD19 or BCMA. This strategy facilitates major histocompatibility complex (MHC)-independent tumor cell killing. Several bispecific antibodies, including Blinatumomab and Teclistamab, have shown remarkable clinical efficacy in hematological malignancies. This article explores the structural design, mechanisms of action, therapeutic applications and challenges associated with bispecific antibody therapies in cancer immunotherapy.
Monoclonal antibodies have revolutionized cancer treatment by providing highly specific targeting of tumor-associated antigens. However, traditional monoclonal antibodies typically bind a single antigenwhich limits their ability to recruit immune effector cells efficiently.
Bispecific antibodies overcome this limitation by recognizing two different goals at the same time.
This double binding feature allows them to:
-
Bring immune cells into direct contact with tumor cells
-
Activate cytotoxic immune responses
-
Improve the killing of tumor cells
Bispecific antibodies have emerged as a powerful new approach in cancer immunotherapyespecially for haematological malignancies such as leukaemia, lymphoma and multiple myeloma.
Bispecific antibodies are engineered to contain two antigen binding sites with different specificities.
Several structural formats have been developed.
IgG-like bispecific antibodies
These molecules resemble conventional antibodies, but contain engineered heavy and light chains that allow binding to two targets.
The benefits include:
Bispecific T-Cell Engagers (BiTEs)
BiTE molecules consist of two single-chain variable fragments (scFvs) connected by a flexible linker.
Key features include:
-
Small molecular size
-
Absence of Fc domain
-
Rapid tissue penetration
A well-known example is Blinatumomabwhich targets CD19 and CD3.
The primary mechanism of bispecific antibodies involves redirection of immune cells.
Most cancer-targeting bispecific antibodies bind:
This interaction forms a artificial immunological synapse between the T cell and the tumor cell.
T cell activation
Binding of CD3 triggers T-cell receptor signaling pathways including:
These signaling events activate transcription factors such as:
Tumor cell killing
Activated T cells eliminate tumor cells through several mechanisms:
Perforin-granzyme pathway
Perforin forms pores in the tumor cell membrane, allowing granzyme B to enter and induce apoptosis.
Cytokine release
Activated T cells produce cytokines such as:
Serial murder
Individual T cells can destroy multiple tumor cells sequentially.
Bispecific antibodies can be categorized based on their mechanisms and targets.
T-Cell Engagers
These antibodies recruit T cells to tumor cells by targeting CD3.
Examples include:
Dual Tumor Antigen Targeting Antibodies
Some bispecific antibodies bind two tumor-associated antigens simultaneously.
This strategy may reduce tumor escape caused by antigen loss.
Immune Checkpoint Bispecific antibodies
These molecules combine checkpoint blockade with tumor targeting to enhance immune activation.
Bispecific antibodies have shown significant clinical success in several cancers.
Acute lymphocytic leukemia
Blinatumomab targets CD19 on B cells and CD3 on T cellswhich enables effective treatment of relapsed or refractory B-cell acute lymphoblastic leukemia.
Myelomatosis
Teclistamab targets BCMA on plasma cells and CD3 on T cellswhich leads to strong immune-mediated tumor killing.
Non-Hodgkin lymphoma
Several CD20-targeted bispecific antibodies are being developed for lymphoma treatment.
Bispecific antibodies offer several advantages over conventional therapies.
High specificity
They selectively target tumor cells while recruiting immune effector cells.
Off the shelf item available
Unlike CAR-T therapy, bispecific antibodies do not require patient-specific production.
Quick start of treatment
Patients can receive treatment without waiting for cell technology.
Despite their advantages, bispecific antibodies also present several challenges.
Cytokine Release Syndrome (CRS)
Rapid T-cell activation can trigger systemic inflammation.
Neurotoxicity
Some patients may develop immune effector cell-associated neurotoxicity syndrome.
Antigen escape
Tumor cells can lose the targeted antigen, reducing the effectiveness of the treatment.
Next-generation bispecific antibodies are being designed to improve therapeutic outcomes.
Emerging strategies include:
-
Trispecific antibodies directed against three antigens
-
BiTE molecules with extended half-life
-
Combination immunotherapy approaches
These innovations aim to improve immune activation and prevent tumor resistance.
Bispecific antibodies represent a major breakthrough in cancer immunotherapy by enabling precise immune cell redirection against malignant cells. Their ability to bridge the gap between T cells and tumor cells allows efficient MHC-independent cytotoxicity, overcoming many limitations of conventional therapies. Approved agents such as Blinatumomab and Teclistamab have already changed treatment options for leukemia and multiple myeloma. Continued advances in antibody technology and combination immunotherapy strategies are expected to expand the clinical application of bispecific antibodies and further improve cancer treatment outcomes.
Q1. What are bispecific antibodies?
Bispecific antibodies are engineered antibodies that are able to bind two different antigens at the same time.
Q2. How do bispecific antibodies kill cancer cells?
They recruit immune cells such as T cells to tumor cells, enabling targeted immune-mediated cytotoxicity.
Q3. Which cancers are treated with bispecific antibodies?
Bispecific antibodies are used in leukaemia, lymphoma and multiple myeloma.
Q4. What is the difference between bispecific antibodies and CAR-T therapy?
Bispecific antibodies redirect existing T cells, while CAR-T therapy involves genetically modifying the patient’s T cells.
Q5. What are the main side effects?
Common toxicities include cytokine release syndrome, infections, and neurotoxicity.
